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Little is known about the mechanisms governing
neonatal growth and maturation of organs. Here we
demonstrate that calcineurin/Nuclear Factor of Acti-
vated T cells (Cn/NFAT) signaling regulates neonatal
pancreatic development in mouse and human islets.
Inactivation of calcineurin b1 (Cnb1) in mouse islets
impaired dense core granule biogenesis, decreased
insulin secretion, and reduced cell proliferation and
mass, culminating in lethal diabetes. Pancreatic
b cells lacking Cnb1 failed to express genes revealed
to be direct NFAT targets required for replication,
insulin storage, and secretion. In contrast, glucoki-
nase activation stimulated Cn-dependent expres-
sion of these genes. Calcineurin inhibitors, such as
tacrolimus, used for human immunosuppression,
induce diabetes. Tacrolimus exposure reduced Cn/
NFAT-dependent expression of factors essential for
insulin dense core granule formation and secretion
and neonatal b cell proliferation, consistent with our
genetic studies. Discovery of conserved pathways
regulating b cell maturation and proliferation sug-
gests new strategies for controlling b cell growth or
replacement in human islet diseases.
INTRODUCTION
Defects in b cell function and number underlie many human
diseases, most notably diabetes mellitus. Emerging strategies
to achieve replacement or regeneration of pancreatic b cells
rely on knowledge about b cell development and growth. b cells
form in the embryonic pancreas (Seymour and Sander, 2011),
and after birth, normal b cell development culminates in two
crucialmilestones. First, enhancementof glucosesensing, insulin
production per cell, and increaseof insulin-containingdensecore
secretory granules, result in the maturation of b cell stimulus-
secretion coupling (Bruin et al., 2008; Kim et al., 2006). Second,
proliferation in neonatal mice and human islets leads to expan-
sion and establishment of appropriate b cell mass (Georgia andDBhushan, 2004; Meier et al., 2008; Teta et al., 2005). Defective
b cell maturation or growth promotes pathogenesis of diabetes
and other diseases (McKnight et al., 2010). Despite the impor-
tance of b cell functional maturation and expansion to human
health, little is knownabout themechanismscontrollingandcoor-
dinating these crucial steps of b cell development.
To achieve effective glucose sensing and insulin secretion,
b cells enhance expression of genes encoding hallmark factors,
including Preproinsulin, glucose transporters (like Glut2 and
Glucokinase), and the transcription factor Pdx1, during the first
3 postnatal weeks in mice (Aguayo-Mazzucato et al., 2011;
Jermendy et al., 2011). In b cells, processed insulin is stored in
secretory granules that have an electron-dense core in ultra-
structural analysis (Kim et al., 2006). These intracellular dense
core granules (DCGs) harbor several principal protein compo-
nents, including the hormones insulin and islet amyloid polypep-
tide (IAPP), granins encoded by chromogranin A (ChgA) and
chromogranin B (ChgB), and transmembrane proteins like IA2
(also called ICA152) (Kim et al., 2006; Suckale and Solimena,
2010). Prior studies suggest that IA2 is an important regulator
of DCG formation and insulin secretion via linked transcriptional
and posttranscriptional mechanisms (Harashima et al., 2005;
Mziaut et al., 2006; Saeki et al., 2002). For example, studies of
immortalized b cell lines suggest that depolarization stimulates
Ca2+-dependent cleavage of IA2 to induce transcription of genes
encoding Insulin, Prohormone convertase 1/3, and IA2 itself
(Mziaut et al., 2006; Trajkovski et al., 2004). Other studies
suggest that IA2 is necessary and sufficient for regulating DCG
number in the mouse MIN6 b cell line (Harashima et al., 2005).
These in vitro studies suggest how activity-dependent regulation
maintains DCGs in adult b cells, but it remains unclear how
Ca2+-dependent b cell pathways might regulate transcription
of hallmark DCG components like granins and IAPP or how
b cell DCG formation is regulated in vivo.
In concert with their maturation, b cells replicate, and this b cell
expansion is postulated to modulate diabetes susceptibility
(Butler et al., 2007). Studies have identified regulators required
for neonatal b cell replication and establishment of b cell mass,
including cyclin dependent kinase 4 (Cdk4) and D type cyclins
(Georgia and Bhushan, 2004; Kushner et al., 2005; Rane et al.,
1999), the transcription factor FoxM1 (Zhang et al., 2006), and
other factors. Islet CyclinD2 (encoded by CcnD2) and FoxM1
protein levels are highest in neonatal mice, then decline inevelopmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc. 21
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regulate and limit b cell proliferation, but this possibility has not
been previously explored. Moreover, it is unknown if these or
other factors regulate neonatal b cell expansion in humans (Davis
et al., 2010; Heit et al., 2006b).
Glucose signaling is a physiological regulator of b cell func-
tional maturation and proliferation. Glucokinase is a crucial regu-
lator of b cell glucosemetabolism, and prior studies demonstrate
that glucokinase activation stimulates Ca2+ transients and depo-
larization, which in turn enhance b cell production of insulin
(Lawrence et al., 2001), insulin secretion (Grimsby et al., 2003),
and proliferation (Pechhold et al., 2009; Porat et al., 2011;
Salpeter et al., 2011). Glucokinase mRNA and activity increase
during the period of postnatal b cell growth and maturation
(Aguayo-Mazzucato et al., 2011; Rozzo et al., 2009; Taniguchi
et al., 2000); thus, glucokinase regulated depolarization and
Ca2+ signaling may be physiological regulators of pathways gov-
erning b cell proliferation and functional specialization. However,
the identity of these pathways remains unclear.
The calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT)
pathway regulates gene transcription to coordinate proliferation,
survival, and differentiation of diverse cell types, including
lymphocytes and neurons (Wu et al., 2007). Calcineurin is a
Ca2+-activated serine/threonine phosphatase required for acti-
vation of the NFATc family of transcription factors (NFATc1-c4).
With sustained rises in intracellular Ca2+, calcineurin activation
leads to dephosphorylation of NFATc proteins and other
substrates (Crabtree and Olson, 2002), a step permitting NFATc
nuclear translocation and regulation of gene transcription. A role
for Cn/NFAT in human b cell function has been indirectly inferred
from the striking observation that 10%–30%of patients requiring
immunosuppression with calcineurin inhibitors, like tacrolimus
(FK506), develop diabetes mellitus (reviewed in Heit, 2007). We
previously reported (Heit et al., 2006a) a role for Cn/NFAT
signaling in adult mouse pancreatic b cells. Conditional genetic
disruption of Cn/NFAT signaling in that study, however, resulted
in a nonlethal adult phenotype, where b cell development was
not investigated. b cell proliferation and mass from birth through
8 weeks of age was indistinguishable from littermate controls,
and by 10 weeks, these mice developed mild hyperglycemia
accompanied by a reduced b cell mass. However, a role for
Cn/NFAT in insulin secretion was not established. Here, we
used conditional genetics to inactivate Cnb1 in neonatal islets,
revealing a requirement for Cn/NFAT signaling in neonatal
b cell development, including DCG biogenesis, functional matu-
ration, and mass establishment. Additionally, studies of islets
from young human subjects show that Cn/NFAT-regulated
mechanisms governing DCG formation and b cell replication
are conserved in humans. Changes of gene expression in human
islets exposed to FK506 described here also unveil molecular
and cellular rationales for the long-standing clinical observation
that calcineurin inhibitors promote diabetes mellitus.
RESULTS
Lethal Postnatal Diabetes from Loss of Pancreatic Islet
Cn/NFAT Signaling
To investigate Cn/NFAT regulation of postnatal b cell develop-
ment, we intercrossed mice (Figure S1A available online) to22 Developmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc.produce progeny harboring a Cnb1 null allele (Cnb1D), a Cre
recombinase-sensitive conditional allele (Cnb1lox) (Winslow
et al., 2006), and Ngn3-Cre, which produces Cre in pancreatic
endocrine progenitors (Schonhoff et al., 2004). On postnatal
day 1 (P1), Ngn3-Cre; Cnb1D/lox mice (hereafter nCnb1KO) had
normal b cell mass (Figures 1A and 1B), were born at expected
mendelian frequency (l2 = 1.452, p = 0.2282), and had normal
hormone+ islet cell composition (Figure S1B). Consistent with
these findings, serum glucose levels in nCnb1KO mice were
indistinguishable from littermate controls before P20 (Figure 1C
and data not shown). Thus, islet developmentwas not detectably
disrupted in embryonic and newborn nCnb1KO mice.
Cnb1 mRNA levels were significantly reduced in postnatal
nCnb1KO islets (Figure S1C) accompanied by reduced nuclear
localization and levels of NFATc1 in nCnb1KO b cells (Fig-
ure S1D), consistent with evidence of transcriptional autoregula-
tion by Nfatc1 (Serfling et al., 2006). By weaning at P20–P21,
nCnb1KOmice were overtly diabetic, with severe hyperglycemia
(Figure 1C) and significant weight loss (Figure S1E). By 12 weeks
of age only 20% of nCnb1KOmice were viable (Figure 1D). Thus,
Cnb1 inactivation in islet progenitors produced lethal diabetes in
young mice. Insulin challenge suggested systemic insulin sensi-
tivity was unaffected in nCnb1KO mice (Figure S1F). However,
intraperitoneal glucose challenge revealed impaired glucose
tolerance in nCnb1KO mice (Figure 1E). Serum insulin levels
during ad libitum feeding were markedly reduced in nCnb1KO
mice by P26 (Figure 1F), suggesting severe b cell defects. By
contrast, neither serum glucagon levels nor a cell mass were
detectably affected in nCnb1KO mice (Figures 1G and 1H). We
did not detect behavioral defects like those previously described
in mice with brain-specific calcineurin inactivation or inhibition
(Malleret et al., 2001). Development of other pancreatic islet
cells, including delta (somatostatin), pancreatic polypeptide
(PP), and epsilon (ghrelin) cells also appeared unchanged in
nCnb1KO mice compared to controls (Figures S1B and S1H).
Additionally, Pdx1-Cre; Cnb1D/lox (pCnb1KO) mice, in which
Cre is expressed from cis-regulatory elements of the pancreatic
duodenal homeobox 1 (Pdx1) promoter (Gu et al., 2002), phe-
nocopied nCnb1KO mice. pCnb1KO mice had no reduction in
b cell mass at birth but developed lethal diabetes in the early
postnatal period (Figures S1I and S1J). Thus, disrupted neonatal
b cell development contributed to the lethal diabetes in
nCnb1KO mice, and we investigated nCnb1KO b cell function
and growth.
Neonatal b Cell Development Requires Cnb1
We postulated that b cell Cnb1 deficiency might compromise
b cell function or growth. Prior to diabetes onset, insulin content
was reduced by 50% in nCnb1KO islets compared to controls
(Figure 2A). In addition, nCnb1KO b cells had severely impaired
insulin secretion. Cultured islets from prediabetic nCnb1KO P20
mice showed no increase in insulin secretion on glucose chal-
lenge (Figure 2B). Likewise, insulin secretion stimulated by argi-
nine was significantly blunted in nCnb1KO islets (Figure 2B).
Thus, insulin content and secretion were reduced in nCnb1KO
islets. During neonatal b cell maturation, expression of insulin 2
(Ins2), Pdx1, Glut2, and glucokinase (Gck) increases (Aguayo-
Mazzucato et al., 2011; Jermendy et al., 2011). Levels of mRNAs
encoding all of these factors were reduced in islets from
Figure 1. nCnb1KO Mice Develop Severe Postnatal Diabetes, Hypoinsulinemia, and Early Onset Lethality
(A and B) Representative insulin immunostaining and quantification of total b cell area/Pancreatic area (in percentage) in postnatal day 1 (P1) control (black bar)
and nCnb1KO (gray bar) pancreas (n = 3 per genotype).
(C) Blood glucose levels of postnatal nCnb1KO mice (gray lines) and littermate controls (black lines) during ad libitum feeding (n = 4 per genotype minimum per
time point).
(D) Percent survival of aging mice (n = 31, controls, black lines; n = 14, nCnb1KO, gray lines).
(E) Glucose tolerance test performed on P19, normoglycemic mice (n = 5, controls, black; n = 4, nCnb1KO, gray). Inset, area under the curve calculated for
indicated genotypes.
(F and G) Serum insulin (F) and serum glucagon (G) levels from fasted P26 mice.
(H) a cell mass in P26 mice. All data are from both female and male mice and represented as means ± SEM. *p < 0.05, **p < 0.025, ***p < 0.002. x, not
significant (n.s.).
See also Figure S1.
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noprecipitation (ChIP) studies of wild-type (WT) P20 islets
revealed association of NFATc1 at cis-regulatory elements in
the Ins2 and Gck genes (Figures S2A and S2B), suggesting
that NFATc1 directly regulates neonatal islet expression of these
genes. Immunohistology supported these findings, revealing
reductions of Insulin, Glut2, and Pdx1 protein in P20 nCnb1KO
islets (Figures 2D, S2C, and S2D). However, expression of
Hif1a, which encodes another b cell metabolic regulator (Cheng
et al., 2010), was unaltered in nCnb1KO islets (Figure S1C). Thus,
Cn/NFAT signaling is required during b cell maturation for
expression of Insulin, Pdx1, Glut2, and Gck.
Cn/NFATSignalingRegulatesbCell DenseCoreGranule
Formation
To determine if Cn/NFAT signaling regulates DCG formation, we
investigated DCGs in nCnb1KO mutant and control islets. We
used transmission electron microscopy criteria (Pictet et al.,
1972) to quantify DCG subsets, including mature, immature,
crystal-containing, and empty DCGs (Figures 3A and 3B).
Compared to control islets, b cells in nCnb1KO islets from predi-
abetic P20 mice had a 40% decrease in average DCG number
(Figure 3C). Levels of mature DCGs were also decreased in
nCnb1KO b cells, matched by an increase of immature DCGs
(Figure 3D). These results suggest that Cn/NFAT signaling is
required for formation and maturation of DCGs.
Genes encoding DCGs proteins (reviewed in Suckale and
Solimena, 2010) include Insulin, chromogranin A (ChgA),
chromogranin B (ChgB), islet amyloid polypeptide (IAPP), andDthe protein tyrosine phosphatase receptor IA2. mRNA and
protein levels of ChgA, ChgB, IAPP, and IA2 were all decreased
in nCnb1KO islets (Figures 3E and 3G–3J). To validate these find-
ings, we exposed islets isolated from WT P20 mice to FK506.
Compared to islets exposed to vehicle, islets exposed to
FK506 had significantly reduced levels of Ins1, Ins2, ChgA,
ChgB, IAPP, and IA2mRNA. By contrast, levels of mRNA encod-
ing a regulator of insulin secretion, HNF4a, remained unchanged
(Figure 3F). Thus, genetic and pharmacological studies provide
evidence that Cnb1 is required for expression of hallmark
components of b cell DCGs. We next used ChIP to investigate
links between Cnb1 and NFAT transcriptional regulation of these
genes. We found consensus NFAT-binding sites in the promoter
regions of ChgA, ChgB, and IA2, but not IAPP (Figure 3K; see
Experimental Procedures). ChIP studies of neonatal WT islets
revealed significant association of NFATc1 at a subset of sites
in ChgA, ChgB, and IA2 compared to IgG controls (Figure 3K).
In WT islets exposed to FK506, NFATc1 binding at ChgA,
ChgB, and IA2 promoters was reduced to levels comparable
to IgG controls (Figure 3K). These results suggest that NFATc1
directly regulates Cn-dependent expression of genes encoding
hallmark b cell DCG components.
To determine whether NFATc1 was sufficient to induce levels
of DCG components, we expressed human NFATc1 (hNFATc1)
(Beals et al., 1997) in the murine b cell line MIN6. Transfected
or control cells were exposed to ionomycin and phorbol
12-myristate 13-acetate (PMA), factors that stimulate NFAT
nuclear localization and activity (Beals et al., 1997), or to vehicle.
Consistent with studies revealing NFATc1 autoregulationevelopmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc. 23
Figure 2. Decreased Insulin Production and Secretion in nCnb1KO Islets
(A) Whole islet insulin content by insulin EIA in size-matched control (black bars) and nCnb1KO (gray bars) islets assessed on postnatal day 20 (P20).
(B) Glucose-stimulated (left) and arginine-stimulated (right) insulin secretion in static culture assays of islets fromP20, normoglycemic nCnb1KOand controlmice.
(C) Quantitative real-time PCR (qRT-PCR) of b cell factors involved in insulin production and secretion, including Insulin 2 (Ins2), pancreatic and duodenal
homeobox 1 (Pdx1), glucose transporter 2 (Glut2), and glucokinase (Gck) in P20 nCnb1KO islets as compared to size-matched islets from littermate controls (n = 4
per genotype). All data presented as means ± SEM. *p < 0.05, **p < 0.025, ***p < 0.002. x, not significant (n.s.).
(D) Immunohistochemical detection of b cell factors Insulin and Glut2 in P20 nCnb1KO and control pancreatic islets. Scale bar = 10 mM.
See also Figure S2.
Developmental Cell
Cn/NFAT Control of b Cell Growth and Maturation(Serfling et al., 2006), we observed that murine NFATc1
(mNFATc1) mRNA increased in MIN6 cells transfected with
hNFAT and induced with ionomycin/PMA (Figure 3L). By
contrast mNFATc1 levels were not elevated in MIN6 cells ex-
pressing hNFATc1 exposed to vehicle (Figure 3L). Levels of
mRNAs encoding the NFAT targets ChgA, ChgB, and IA2 also
increased in hNFATc-transfected MIN6 cells exposed to iono-
mycin/PMA (Figure 3L). By contrast, IAPP mRNA levels were
not increased, consistent with the lack of NFATc1 binding sites
discussed previously. Thus, Cn/NFAT signaling is sufficient to
stimulate expression of genes encoding b cell DCG components.
To investigate if Cn/NFAT regulation of DCG components was
conserved, we studied cultured human islets exposed to FK506
or vehicle control. Compared to control islets, we found reduc-
tion of mRNAs encoding INS, CHGA, CHGB, IAPP, and IA2 in
islets exposed to FK506 (Figure 4A). By contrast, islet levels of
mRNA encoding HNF4a were unaffected by FK506 (Figure 4A).
Thus, similar to findings from mouse islets (Figures 3E and 3F),
expression of genes encoding the principal DCG components
in human islets was reduced by calcineurin inhibition. We next
used ChIP to investigate if NFAT associated with cis-regulatory
elements in CHGA, CHGB, IAPP, and IA2. Based on discovery
of candidate NFAT-binding sites within the promoter regions of
CHGA, CHGB, IAPP, and IA2 (Figure 4B; see Experimental24 Developmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc.Procedures), ChIP revealed significant association of NFATc1
at a subset of sites in all these loci, compared to IgG controls
(Figures 4B and 4C). In human islets exposed to FK506, NFATc1
binding at these targets was consistently reduced (Figure 4B).
Thus, Cn/NFAT signaling regulates expression of hallmark
b cell DCG components in human islets.
Proliferation to Establish Neonatal bCell Mass Requires
Cn/NFAT Signaling
To investigate whether Cn/NFAT signaling regulates postnatal
b cell proliferation, we examined nCnb1KO pancreata. Com-
pared to littermate controls, nCnb1KO mice at P26 exhibited a
7-fold decrease in b cell mass (Figures 5A and 5B). In nCnb1KO
mice at P26 we observed a 3-fold reduction in b cells expressing
the proliferation marker Ki67, indicating impaired b cell prolifera-
tion (Figure 5C). By contrast, the percentage of b cells producing
activated caspase 3, a marker of apoptosis, was not significantly
increased (Figure S1G). Thus,Cnb1 is required for neonatal b cell
proliferation and expansion. To identify the basis for impaired
expansion of juvenile b cells lackingCnb1, wemeasured expres-
sion of known regulators of neonatal b cell proliferation, including
cyclin D1 (CcnD1), cyclin D2 (CcnD2), cyclin-dependent kinase 4
(Cdk4), and the Forkhead box (Fox) factor FoxM1 (Kushner et al.,
2005; Rane et al., 1999; Zhang et al., 2006). In islets from
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were significantly reduced compared to levels in size- and
age-matched control islets. Likewise, nCnb1KO islet mRNA
levels of Cyclin A2 (CcnA2), another regulator of the G1-to-S
phase transition, were also reduced (Figure 5D). By contrast,
CcnD1 and Cdk4 mRNAs were not detectably reduced in
nCnb1KO islets (Figure 5D). To validate these findings, we
exposed neonatal, WT islets to FK506. Like in nCnb1KO islets,
levels of CcnA2, CcnD2, and FoxM1 mRNAs were significantly
decreased (Figure 5E). Immunohistology revealed accompa-
nying reductions of CcnD2 and FoxM1 protein in nCnb1KO
b cell nuclei (Figures 5F and 5G). These results reveal a require-
ment for Cn/NFAT signaling during a crucial neonatal stage of
b cell proliferation and expansion.
CcnA2, CcnD2, and FoxM1 Regulation in Mouse
and Human Islets by NFATc1
To investigateCcnD2, FoxM1, andCcnA2 regulation in islets, we
measured mRNA levels encoding these factors in b cells purified
by FACS from juvenile and adult MIP-GFP mouse islets
(Sugiyama et al., 2007). Levels of mRNAs encoding CcnD2,
FoxM1 (Ackermann Misfeldt et al., 2008), and CcnA2 were
enriched in juvenile b cells, then declined in adult b cells
(Figure 5H). By contrast, mRNA levels encoding the cyclin-
dependent kinase inhibitor p16Ink4a increased during this interval
(Figure 5I), confirming prior results (Chen et al., 2009). Age-
dependent b cell expression of CcnD2 and FoxM1 mRNA
reported here is consistent with prior studies of dynamic
CyclinD2 and FoxM1 protein abundance in mouse b cells
(Georgia and Bhushan, 2004; Zhang et al., 2006). We identified
consensus promoter-proximal NFAT-binding sites in mouse
CcnD2, FoxM1, and CcnA2 loci (Figure 5J). NFATc1 protein
association at these sites in WT neonatal islets was revealed
by ChIP and exposure of islets to FK506 consistently reduced
NFATc1 binding to background levels (Figure 5J). Thus, NFATc1
directs Cn-dependent expression of known regulators of
neonatal b cell proliferation.
To test whether NFATc1 was sufficient to induce the expres-
sion of these cell cycle regulators, we expressed human NFATc1
(hNFATc1) (Beals et al., 1997) in the MIN6 b cell line. hNFATc1-
transfected cells were then exposed to ionomycin/PMA or to
vehicle. hNFATc1 transfection followed by ionomycin/PMA
treatment increased expression of CcnA2 and FoxM1, com-
pared to controls (Figure 5K). Baseline levels of CcnD2 in MIN6
cells are known to be elevated (Cozar-Castellano et al., 2006);
so, as expected, hNFATc1 transfection with ionomycin/PMA
treatment did not further increase CcnD2 mRNA in MIN6 cells
(Figure 5K). Thus, Cn/NFAT signaling regulates CcnA2, CcnD2,
and FoxM1 expression and b cell proliferation in postnatal
mouse islets.
Human b cell proliferation, assessed by Ki67 staining, is high-
est in children less than 5–10 years of age (Meier et al., 2008). To
test the relevance of our findings to human b cell proliferation, we
measured mRNA levels of CCNA2, CCND2, and FOXM1 in islets
isolated from donors aged 1–5 years and control adult donors.
mRNAs encoding CCNA2, CCND2, and FOXM1 were higher in
islets purified from young donors than in islets from adults
(Figures 6A–6C). By contrast, levels of mRNA encoding cyclin-
dependent kinase 2 (CDK2) did not change significantly withDhuman islet age (Figure 6D). Thus, our findings reveal elevated
islet expression of CCNA2, CCND2, and FOXM1 during a period
of established physiologic human b cell expansion. Based on
similarities to our findings in mice, we tested whether Cn/NFAT
signaling governs human islet CCNA2, CCND2, and FOXM1
expression. We identified consensus NFAT-binding sites in the
promoter regions of human CCNA2, CCND2, and FOXM1 (Fig-
ure 6E), and ChIP revealed FK506-sensitive NFATc1 association
at these sites in neonatal human islets (Figure 6E). Next, we
exposed human islets to FK506 or vehicle control, and quantita-
tive real-time PCR (qRT-PCR) revealed that CCNA2, CCND2,
and FOXM1 mRNA levels were significantly decreased in
FK506-exposed islets compared to control islets (Figure 6F).
Consistent with these findings, exposure of cultured neonatal
human islets to FK506 reduced b cell BrdU incoporation by
nearly 3-fold, compared to islets exposed to vehicle control
(Figures 6G and 6H). Collectively, these findings provide
evidence that Cn/NFAT signaling regulates CCNA2, CCND2,
and FOXM1 expression and b cell proliferation in human islets.
Glucokinase Activator Induces NFAT Target Genes
Governing b Cell Growth and Maturation
Our findings suggested that Cn/NFAT signaling is developmen-
tally regulated in postnatal islets. If so, we predicted that expres-
sion of mRNAs encoding NFATc1 and other factors would be
elevated in neonatal islets because NFATc1 activates expres-
sion of itself and other pathway components (Arron et al.,
2006; Serfling et al., 2006). Consistent with this possibility, we
observed that levels of mRNAs encoding NFATc1, NFATc2,
and NFATc4 were higher in islets from P10 mice compared to
those in P28 islets (Figure S3A). FACS purification confirmed
that NFATc1 mRNA levels were approximately 50% greater in
b cells from P5–P15 islets than those in b cells from adult mice
(Figure S3B). Thus, expression and activity of Cn/NFAT signaling
appears to be enhanced in neonatal islets when expression of
NFAT targets governing b cell proliferation and maturation
peaks.
Prior work suggests that glucokinase activation is a
physiological mechanism for stimulating depolarization and
Ca2+-dependent b cell proliferation and maturation (reviewed in
Salpeter et al., 2011). Thus, we postulated that b cell Cn/NFAT
signaling might be induced by glucokinase activators. Consis-
tent with this possibility, we found that the glucokinase activator
(GKA) R0-28-1675 (Matschinsky, 2009) increased NFATc1
mRNA by 50% in cultured P10 islets (Figure 7A), compared to
islets exposed to vehicle control. This induction was blocked
by simultaneous exposure of WT islets to FK506 and GKA (Fig-
ure 7A), a result supported by our finding that GKA-induced
expression of NFATc1 was also blocked in nCnb1KO islets (Fig-
ure 7A). Ins2, ChgA, ChgB, IAPP, and IA2 were significantly
increased in neonatal P10 islets exposed to GKA, an effect
blunted or eliminated by FK506 (Figures 7B and 7C). Similar
induction of mRNAs encoding b cell cycle regulators CcnA2,
CcnD2, and FoxM1 were observed in P10 islets exposed to
R0-28-1675; again, these effects were attenuated or blocked
by simultaneous exposure to FK506 (Figure 7D). Together, these
findings suggest that glucokinase activation of Cn/NFAT
signaling in postnatal islets may regulate crucial regulators of
b cell function and proliferation.evelopmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc. 25
Figure 3. Dense Core Granule Biogenesis and Maturation in Mouse b Cells Requires Cn/NFAT Signaling
(A) Transmission electron micrographs of postnatal day 20 (P20) control and nCnb1KO b cells.
(B) Representative pictures of the four insulin granule types: (1) mature, (2) immature, (3) crystal-containing, and (4) empty.
(C and D) Quantification and morphometric analysis of dense core granules (DCGs) fromWT (black bars) and nCnb1KO (gray bars) b cells showing (C) number of
granules per unit area and (D) abundance of the different granule subtypes (as a percentage of the total number of granules).
(E) qRT-PCR of DCG components in P20 nCnb1KO islets as compared to size-matched islets from littermate controls (n = 4 per genotype). Dashed line
represents control levels normalized to 1.0.
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Progress in creating replacement islets from renewable sources,
like human stem cell lines, is limited by a lack of knowledge about
physiological mechanisms promoting development of functional
insulin-secreting b cells (McKnight et al., 2010). Likewise, the
promise of advances in human islet transplantation is con-
strained by a demand for replacement b cells that exceeds
supply (Meier et al., 2008). Thus, there is intense interest in
understanding mechanisms regulating the in vivo maturation
and proliferation of pancreatic islet b cells. Here we report that
the Cn/NFAT pathway regulates maturation and expansion of
functional b cells in both mouse and human islets (Figure 7E).
During physiological growth in neonatal mice and humans,
islet b cells adapt by enhancing their hallmark functions,
including glucose sensing, insulin production, DCG biogenesis,
and stimulus-secretion coupling (Bruin et al., 2008; Kim et al.,
2006; Suckale and Solimena, 2010). This functional maturation
likely reflects the shift from intrauterine energy sources to the
postnatal diet (Fowden and Hill, 2001). Expression of genes
encoding the effectors of these functional adaptations, including
Insulin2, Glut2, Glucokinase, Pdx1, ChromograninA, and IA2,
increases in neonatal mice (Aguayo-Mazzucato et al., 2011;
Jermendy et al., 2011; C. Benitez and S.K.K., unpublished
data). Prior studies (Ahlgren et al., 1998; Gu et al., 2010; Mziaut
et al., 2008; Zhang et al., 2005) suggest that subsets of these
factors in adult islets or cell lines may be governed by tran-
scriptional regulators, including MafA, Pdx1, NeuroD1, IA2,
and Stat5. Other studies have previously demonstrated reg-
ulation of Insulin by NFATc1 in the b cell line MIN6 and in adult
islets (Heit et al., 2006a; Lawrence et al., 2001). However,
the basis for dynamic changes in neonatal expression of these
b cell factors in mouse or human islets has not been established.
The findings here demonstrate in vivo roles for Cn/NFAT in
mouse islet maturation and in controlling expression of factors
essential for hallmark b cell functions in neonatal human
islets. We also present evidence that NFATc1 is sufficient to
activate expression of target genes encoding b cell cycle reg-
ulators and dense core granule components. These findings
do not rule out roles for other calcineurin-regulated factors in
neonatal b cell development. In addition to NFATs, calcineurin
has other important targets, including TORC2 and Erk1/2
(Arnette et al., 2003; Lawrence et al., 2005; Le Lay et al., 2009).
Although there is evidence for Raf/Erk1/2 signaling in insulin
secretion (Longuet et al., 2005), glucose regulation was not
detectably perturbed in mice lacking TORC2 (Le Lay et al.,
2009). Additional studies are needed to address the possibility
that calcineurin-dependent Erk1/2 activation may regulate post-
natal b cell development.(F) qRT-PCR of b cell factors and DCG components in P20 islets from wild-typ
72 hr (n = 5).
(G–J) Immunohistochemical detection of DCG components ChgA (G), ChgB (H),
(K) Chromatin immunoprecipitation (ChIP) of NFATc1 at indicated loci in islets iso
either vehicle (EtOH) or FK506 (10 mM) (n = 4 per condition). ChIP data are prese
leftmost data bar (black).
(L) Relative mRNA levels of indicated genes after in vitro transfection of MIN6 ce
vector (Vector) and treated with either vehicle DMSO or a combination of Ionomy
***p < 0.002. x, not significant (n.s.).
DHow are b cell growth and maturation coordinated in neonatal
islets? Prior reports suggested that glucose metabolism by
glucokinase may link b cell depolarization and Ca2+ influx to
b cell proliferation (Pechhold et al., 2009; Porat et al., 2011; Sal-
peter et al., 2011) and function (Kassem et al., 2010; Terauchi
et al., 1995, 2007; Vionnet et al., 1992). Moreover, neonatal
b cell growth and maturation in rodents is accompanied by
enhanced Ca2+ flux (Navarro-Tableros et al., 2007), requiring
the voltage-gated calcium channel subunit a1D (Namkung
et al., 2001). However, it remained unclear how Ca2+ signals
were connected to genetic programs controlling b cell
growth and maturation. Cn/NFAT signaling is regulated by
Ca2+ transients (reviewed by Crabtree and Olson, 2002), and
Ca2+-regulation of Cn/NFAT activity in b cells has been estab-
lished (Lawrence et al., 2009). Our studies link glucokinase
activation to Cn/NFAT signaling induction in mouse islet b cells.
Thus, findings here suggest that Cn/NFAT signaling is a crucial
pathway that links enhanced glucose metabolism and Ca2+
dynamics to transcriptional regulation that drives b cell prolifera-
tion and maturation in neonatal islets (Figure 7E). We speculate
that further studies may reveal how Cn/NFAT signaling converts
and integrates activity-dependent b cell Ca2+ transients into
gene expression changes that orchestrate b cell developmental
growth and functional maturation. Further studies are also
required to establish if glucokinase activators can stimulate
expression of b cell cycle regulators and hallmark dense core
granule components in human islets in culture and in vivo. If
so, discovery of Cn/NFAT activators might be used to stimulate
proliferation and expansion of functional human b cells produced
from expandable sources, including stem cell lines.
Based on frequency of iatrogenic diabetes mellitus from
FK506 or cyclosporine A (Heit, 2007), we and others postulated
that disrupted Cn/NFAT signaling might impair b cell function
(Heit et al., 2006a; Redmon et al., 1996). Cultured human islets
exposed to FK506 have impaired insulin secretion (Johnson
et al., 2009) and reduced DCG numbers (Bugliani et al., 2009;
Drachenberg et al., 1999), but the molecular basis for these find-
ings remained unclear. Our results argue that impaired islet
insulin secretion from exposure to calcineurin inhibitors reflects
both disrupted expression of b cell secretion regulators, like
Glut2 and Glucokinase, and impaired biogenesis or dynamics
of b cell dense core granules. b cell depolarization may induce
Ca2+-dependent processing of IA2 by the calpain protease,
leading to Stat5 activation and increased expression of IA2 itself
and other DCG components (Mziaut et al., 2006; Trajkovski et al.,
2004). Recent studies have shown that calpain may also activate
calcineurin activity in response to Ca2+ signaling (Chang et al.,
2004), and we show here that Cn/NFAT signaling regulates islet
expression of IA2 andNfatc1. Thus, Ca2+-dependent signaling ine (WT), C57BL/6 male mice treated with FK506 (10 mM) or vehicle (EtOH) for
IAPP (I), and IA2 (J) in P26 nCnb1KO and control islets. Scale bar = 10 mM.
lated and fixed from P20 WT, C57BL/6 mice. Islets were treated for 24 hr with
nted as fold change of signal relative to IgG background with comparisons to
lls with human NFATc1 expression construct (hNFATc1) or empty expression
cin and PMA (I/P). All data presented as means ± SEM. *p < 0.05, **p < 0.025,
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Figure 4. Cn/NFAT Signaling Regulates Expression of DCG Components in Human Islets
(A) Relative quantification of mRNAs encoding indicated DCG components in isolated human islets (n = 3) treated with FK506 (10 mM) or vehicle (EtOH) for 72 hr.
Dashed line represents vehicle-treated control levels normalized to 1.0.
(B) ChIP of NFATc1 on isolated human islets (sample #1: 5 years old, sample #2: 13 years old). Each human sample was divided and treated for 24 hr with either
vehicle (EtOH) or FK506 (10 mM).
(C) Additional adjacent NFAT consensus sites (‘‘Site #2’’) within the indicated gene promoter regions did not bind NFATc1 (see also Table S2). ChIP data are
presented as fold change of NFATc1 signal (white bar) or NFATc1+FK506 (gray bar) relative to IgG (black bar) control signal. All data presented as means ± SEM.
*p < 0.05, **p < 0.025, ***p < 0.002. yp < 0.15. x, not significant (n.s.)
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Cn/NFAT Control of b Cell Growth and Maturationb cells may lead both to autoactivation and cross-activation of
transcriptional regulators that control expression and assembly
of key DCG components, as well as essential glucose sensing
factors, like glucose transporters and glucokinase. Studies of
cultured cell lines and rodent islets provide evidence that
signaling pathways regulated byGLP1, ERK/MAPK, and glucose
may activate the Cn/NFAT pathway in b cells (Lawrence et al.,
2001, 2005, 2009). Additional studies are needed to test if factors
that modulate b cell Cn/NFAT activation may be useful for
promoting maturation of replacement b cells produced from
renewable sources.28 Developmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc.In mice, CyclinD1, CyclinD2, Cdk4, and FoxM1 are required
for b cell proliferation during physiological neonatal growth
(Georgia and Bhushan, 2004; Kushner et al., 2005; Rane et al.,
1999; Zhang et al., 2006). Work here reveals that Cn/NFAT
signaling regulates in vivo mouse b cell expression of CcnD2
and FoxM1, as well as CcnA2, a known regulator of proliferation
in smooth muscle and fibroblasts (Karpurapu et al., 2008;
Tomono et al., 1998). Studies of neonatal mouse islets ex-
posed to FK506 demonstrate Cn-dependent association of
NFATc1 with these loci, supporting the view that NFATc1 regu-
lates expression of these genes. Genetic studies allowing
Figure 5. Mouse Neonatal b Cell Proliferation and Mass Regulated by Cn/NFAT Signaling
(A) Representative insulin stains of Control and nCnb1KO pancreatic tissue at postnatal day 26 (P26).
(B) Quantification of b cell mass by morphometry in control (black bar) and nCnb1KO (gray bar) mice.
(C) Quantification of b cell proliferation by scoring the percentage of Ki67+ b cells in control (black bar) and nCnb1KO (gray bar) pancreatic islets.
(D) Quantification of mRNAs encoding indicated cell cycle regulators in P20 nCnb1KO islets and size-matched control islets (n = 4 per genotype). Dashed line
represents control levels normalized to 1.0.
(E) mRNA quantification of CcnA2, CcnD2, and FoxM1 in P20 islets from WT C57BL/6J male mice treated with FK506 (10 mM) or vehicle (EtOH) for 72 hr (n = 5).
Dashed line represents control levels normalized to 1.0.
(F and G) Immunohistochemical detection of Cyclin D2 (F), gray, or red in merge), and FoxM1 (G), gray, or red in merge) in P26 nCnb1KO and control pancreatic
islets. Insulin (Ins) in green. Scale bar = 10 mM.
(H and I) qRT-PCR time course of cell cycle regulators in FACS-isolated b cells from MIP-GFP mice at indicated ages (n = 4, 2, 3, 2, 2 at each time point,
respectively).
(J) ChIP of NFATc1 on indicated loci from islets isolated and fixed from P20 wild-type, C57BL/6 mice. Islets were treated for 24 hr with either vehicle (EtOH)
or FK506 (10 mM) (n = 4 per condition). ChIP data are presented as fold change of NFATc1 (white bar) or NFATc1+FK506 (gray bar) signal relative to IgG (black bar)
background signal.
(K) Quantification of mRNA levels of indicated genes after in vitro transfection of MIN6 cells with human NFATc1 expression construct (hNFATc1) or empty
expression vector (Vector) treated with either Ionomycin and PMA (I/P) or vehicle DMSO. All data presented as means ± SEM. *p < 0.05, **p < 0.025,
***p < 0.002. x, not significant (n.s.), with comparisons to leftmost data bar (black), unless otherwise noted.
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Cn/NFAT Control of b Cell Growth and Maturationsimultaneous inactivation of the eight alleles encoding NFATc1-
c4 in b cells should test the requirement for these transcriptional
regulators in neonatal b cell proliferation. Collectively, our resultsDsuggest that Cn/NFAT activity governs the expression ofmultiple
cell cycle regulators essential for establishing b cell mass in juve-
nile mice. Here we show that levels of mRNA encoding CCND2,evelopmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc. 29
Figure 6. CCNA2, CCND2, and FOXM1mRNA Levels Peak during the Neonatal Period in Human Islets, and Cn/NFAT Regulates Their Expres-
sion
(A–D) qRT-PCR time course of CCNA2, CCND2, FOXM1, and CDK2mRNA transcript levels in isolated islets from humans of increasing age (n = 2, except time
point ‘‘39-56 y’’, where n = 4).
(E) ChIP of NFATc1 at indiated loci from isolated human islets (sample #1: 5 years old, sample #2: 13 years old) treated for 24 hr with either vehicle (EtOH) or FK506
(10 mM). Note: Sample #1 was only treated with vehicle because of limited islet yield from donor sample. Additional adjacent NFAT consensus sites (‘‘Site #2’’)
within the gene promoter region did not bind NFATc1 (see also Table S2). ChIP data are presented as fold change of NFATc1 signal (white bar) or NFATc1+FK506
(gray bar) relative to IgG (black bar) control signal.
(F) mRNA quantification of indicated genes in isolated human islets (n = 3) treated with FK506 (10 mM) or vehicle (EtOH) for 72 hr. Dashed line represents vehicle-
treated control levels normalized to 1.0.
(G and H) Quantification of BrdU+ insulin+ cells as a percentage of all insulin+ cells in islets isolated from a 4-year-old human donor pancreas. Islets were divided
and exposed to vehicle (DMSO) or FK506 (10 mM) (see Experimental Procedures). (H) Representative immunofluorescence staining of insulin+BrdU+ double-
positive cells (arrowheads) from 4-year-old donor islets. Insulin (green) and BrdU (red). All data presented as means ± SEM. *p < 0.05, **p < 0.025, ***p < 0.002. x,
not significant (n.s.).
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Cn/NFAT Control of b Cell Growth and MaturationFOXM1, and CCNA2 are highest in islets from young human
donors, then decline in adult islets, similar to their age-depen-
dent reduction in mice. Moreover, molecular analysis reveals
that Cn/NFAT signaling is required to sustain expression of these
factors and BrdU incorporation by human neonatal b cells. Addi-
tional studies should also reveal whether age-dependent decline
of human b cell proliferation is linked to attenuation of Cn/NFAT
activity. Thus, our work unveils evolutionarily conserved mecha-
nisms governing human b cell cycle regulation and suggests that
impaired b cell replication may underlie iatrogenic diabetes in
patients exposed to calcineurin inhibitors, like FK506. We
speculate that development of novel Cn/NFAT pathway inhibi-
tors with improved therapeutic index (Bernard et al., 2010) might
prove useful to develop strategies for diseases reflecting
increased b cell mass or function, including congenital or30 Developmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc.acquired hyperinsulinism, nesidioblastosis following bariatric
surgery, insulinomas, and other neuroendocrine cancers.
EXPERIMENTAL PROCEDURES
Animals
Mice harboring theCnb1f orCnb1D alleles were described previously (Winslow
et al., 2006). TransgenicNgn3-Cre, Pdx1-Cre andMIP-EGFPmice were previ-
ously described (Gu et al., 2002; Schonhoff et al., 2004; Hara et al., 2003).
C57/BL6 mice were from Charles River. Mice were used in accordance with
the Institutional Animal Care and Use Committee of Stanford University. See
Supplemental Experimental Procedures for details.
Molecular, Histological, and Electron Microscopy Methods
Standard histology and immunostaining protocols for various proteins on
pancreas or islet sections were described previously (Chen et al., 2009; Heit
et al., 2006a). b cell mass and proliferation were morphometrically quantified
Figure 7. Glucokinase Activator Induces Transcription of NFATc1 and Its Targets in a Calcineurin-Dependent Manner
(A–D) Islets isolated from postnatal (P10) control C57Bl/6 or nCnb1KO mice treated with either vehicle, glucokinase activator (GKA) R0-28-1675 (10 mM) or
GKA+FK506 (10 mM each) for 72 hr (n = 3 minimum per condition). qRT-PCR of (A) NFATc1, (B) Insulin 2, (C) indicated DCG components, and (D) indicated cell
cycle regulators.
(E) Schematic summarizing a role for Cn/NFAT signaling in postnatal b cell (1) maturation and (2) proliferation via the direct transcriptional regulation of key b cell
genes. Ins2 (insulin 2), Pdx1 (pancreatic duodenal homeobox 1), Glut2 (glucose transporter type 2), Gck (glucokinase), ChgA/B (chromogranins A and B), IAPP
(islet amyloid polypeptide), IA2 (ICA512), CcnA2 (cyclinA2), CcnD2 (cyclinD2), and FoxM1 (forkhead homeobox factor M1). All data are from male mice and are
represented as means ± SEM. *p < 0.05, **p < 0.025, ***p < 0.002. x, not significant (n.s.).
See also Figure S3.
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Cn/NFAT Control of b Cell Growth and Maturationand details of these studies and mouse islet isolations, RT-PCRs, and
ChIP analyses are provided in the Supplemental Experimental Procedures.
For culture studies, islets were placed in standard media (RPMI 1640
with 4.5 mM glucose containing 10% FBS and 1% pen/strep) at 37C and
5% CO2. In some experiments islets were maintained in media containing
vehicle (DMSO), glucokinase activator (GKA) R0-28-1675 (10 mM; Axon
Ligands) and/or FK506 (10 mM; LC Laboratories, Woburn, MA, USA) for
72 hr, with media changes every 24 hr. b cells from MIP-EGFP islets were
isolated as previously described (Sugiyama et al., 2007). Analyses were
performed in triplicate and islets from three to six mice of each genotype
were independently tested.
For transmission EM experiments, 50 size-matched islets were isolated by
collagenase perfusion from three prediabetic P20 nCnb1KO mice and three
littermate controls as described above and in the Supplemental Experimental
Procedures. Consecutive 75 to 90 nm sections were taken between, picked on
formvar/carbon coated slot grids (EMS) or 100 mesh Cu grids (EMS). After
contrast staining, sections were observed in a JEOL 1230 TEM at 80 kV and
images captured with a digital camera. Three experiments were performed
by independent researchers blinded to sample identity, with a minimum of
30 b cells scored per genotype per experiment.
Physiological and In Vitro Studies
Glucose and insulin tolerance tests were performed as previously described
(Heit et al., 2006a). Serum insulin and glucagon levels were assessed in P26
mice fasted for 4 hr using the Mouse Insulin Ultrasensitive EIA and Glucagon
ELISA kits (Alpco, Salem, NH, USA). Whole islet insulin content, GSIS and
ASIS batch culture experiments were performed as previously described
(Chen et al., 2009). Each condition was performed in quadruplicate using islets
from at least three mice per genotype and levels of secreted insulin were
normalized to islet DNA content.
MIN6murine insulinoma cells (passage 26; Miyazaki et al., 1990) were trans-
fected using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with 2 mg of
control vector (pcDNA) or DNA permitting expression of human NFATc1DcDNA, as previously described (Beals et al., 1997). Cells grown for 48 hr
were treated with vehicle (DMSO) or a combination of ionomycin (1 mM) and
phorbol 12-myristate 13-acetate (PMA) (25 mM) to activate calcineurin/NFAT.
Eight hours later cells were harvested for mRNA isolation.
Human Islet Studies
Institutional review board approval for research use of tissue was obtained
from Stanford University School of Medicine. Human pancreata were obtained
from previously healthy, nondiabetic organ donors by the National Diseases
Resource Interchange. Islets were isolated by R. Bottino, (University of
Pittsburgh) or at the University of Alabama (S. Bryant and T. Thompson). Seven
independent human islet batches from donors aged 13, 19, and 23months old
or aged 4, 5, 19, and 20 years old, as well as five adult batches from donors of
28, 29, 49, 55, and 56 years old were used in this study. Within 24 hr of
isolation, islets were transferred to fresh islet culture medium and handpicked
after dithizone staining, detailed in the Supplemental Experimental Proce-
dures. One thousand islet equivalents were concentrated and frozen for
mRNA isolation, or prepared for ChIP as described above. BrdU analysis
was performed following exposure to 50 mM BrdU for 24 hr. Islets were immu-
nostained for insulin and BrdU and b cell proliferation rate was determined by
quantifying the percentage of insulin+ and BrdU+ cells. We scored a minimum
of 50 islets and over 2,000 b cells per condition.
Statistical Analysis
Results were expressed as the mean ± SEM. Statistical analysis was per-
formed using the two-tailed or one-tailed, unpaired Student’s t test, with
significance set at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2012.05.014.evelopmental Cell 23, 21–34, July 17, 2012 ª2012 Elsevier Inc. 31
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